Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he will issue guidance to the National Institute for Health and Care Excellence (NICE) on taking steps to ensure (a) unpaid care costs and (b) quality-of-life impacts on unpaid carers are reflected in NICE appraisals of new Alzheimer’s disease treatments.

The Department has no plans to issue guidance to the National Institute for Health and Care Excellence (NICE) to ensure that it takes into account unpaid care costs and quality of life impacts on unpaid carers in appraisals of Alzheimer’s disease treatments. NICE is an independent body and is responsible for the methods and processes that it uses in the development of its technology appraisal recommendations, and develops its recommendations in line with its published health technology evaluations manual.

NICE is currently developing guidance on two disease modifying treatments for Alzheimer’s disease and NICE’s independent Appeal Panel has upheld appeals against its draft recommendations. The Appeal Panel has referred the appraisals back to the Appraisal Committee in order to allow them to reconsider the assessment of the impacts on carers.